CD8A and hepatocellular carcinoma: Taken together, ACAT inhibition increased the anti-tumour potential of endogenous TAA-specific CD8+ T cells within human HCC examined directly ex vivo, as well as increasing the functional avidity of TCR-gene-modified CD8+ T cells.